Analysis of Cardiovascular Complications During Delivery Admissions Among Patients With Systemic Lupus Erythematosus, 2004-2019

This cohort study investigates the association of systemic lupus erythematosus with cardiovascular complications during delivery admissions from 2004 to 2019.

[1]  H. V. Van Spall,et al.  Racial and Socioeconomic Disparities in Cardiovascular Outcomes of Preeclampsia Hospitalizations in the United States 2004-2019 , 2022, JACC. Advances.

[2]  P. Ouyang,et al.  Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. , 2022, Fertility and sterility.

[3]  M. Gulati,et al.  Income disparity and utilization of cardiovascular preventive care services among U.S. adults , 2021, American journal of preventive cardiology.

[4]  Q. Yao,et al.  Polycystic ovary syndrome: epidemiologic assessment of prevalence of systemic rheumatic and autoimmune diseases , 2021, Clinical Rheumatology.

[5]  E. Michos,et al.  Impact of social determinants of health on cardiovascular disease prevention , 2021, Current opinion in cardiology.

[6]  M. Gulati,et al.  Racial Disparities in Cardiovascular Complications With Pregnancy-Induced Hypertension in the United States , 2021, Hypertension.

[7]  A. Stromberg,et al.  Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state , 2021, Lupus Science & Medicine.

[8]  D. Hoyert,et al.  Maternal Mortality Rates in the United States, 2019 , 2021 .

[9]  J. Mejía-Vilet,et al.  The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug , 2021, Frontiers in Medicine.

[10]  A. Morgan,et al.  Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study , 2020, PLoS medicine.

[11]  J. Muñóz-Valle,et al.  Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: A cross-sectional study. , 2020, Clinical immunology.

[12]  F. Chervenak,et al.  Concerning trends in maternal risk factors in the United States: 1989–2018 , 2020, EClinicalMedicine.

[13]  R. Rzepka,et al.  The Role of Inflammation in the Pathogenesis of Preeclampsia , 2020, Mediators of inflammation.

[14]  S. Wilson,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2020, 50 Landmark Papers Every Vascular and Endovascular Surgeon Should Know.

[15]  Wen He,et al.  Maternal and fetal complications associated with systemic lupus erythematosus , 2020, Medicine.

[16]  D. Lloyd‐Jones,et al.  Cardiovascular Health Among Pregnant Women, Aged 20 to 44 Years, in the United States , 2020, Journal of the American Heart Association.

[17]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[18]  T. Hsieh,et al.  Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: A nationwide population-based study. , 2020, Seminars in arthritis and rheumatism.

[19]  C. Gordon,et al.  Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016 , 2019, MMWR. Morbidity and mortality weekly report.

[20]  Harlan M. Krumholz,et al.  Adherence to Methodological Standards in Research Using the National Inpatient Sample , 2017, JAMA.

[21]  C. Ritchlin,et al.  Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs , 2017, Lupus.

[22]  N. Olsen,et al.  Systemic lupus erythematosus diagnosis and management , 2016, Rheumatology.

[23]  N. Afzal,et al.  Polycystic Ovary Syndrome May Be an Autoimmune Disorder , 2016, Scientifica.

[24]  L. Amaral,et al.  The role of inflammation in the pathology of preeclampsia. , 2016, Clinical science.

[25]  P. Libby,et al.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. , 2015, European heart journal.

[26]  E. Svenungsson,et al.  Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus , 2014, Autoimmunity.

[27]  Kent R Bailey,et al.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[28]  D. Isenberg,et al.  Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. , 2009, Rheumatology.

[29]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[30]  S. Appenzeller,et al.  Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors , 2008, Current cardiology reviews.

[31]  G. Hughes,et al.  Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients , 2003, Medicine.

[32]  M. Ward.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[33]  M. Petri,et al.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.

[34]  M. Urowitz,et al.  The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.

[35]  Ariel Williams,et al.  MATERNAL MORTALITY RATES IN THE UNITED STATES , 2019 .

[36]  B. Dijkmans,et al.  Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. , 2008, Clinical and experimental rheumatology.

[37]  D. Gladman,et al.  Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. , 2007, The Journal of rheumatology.

[38]  A. Voss,et al.  A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value , 2005, Clinical Rheumatology.